These observations call for further research into the underlying mechanisms of anemia in plasma cell dyscrasias, as well as the changes occurring in the microenvironment with CD38-targeting agents, to better inform clinical management and improve patient outcomes. This evidence concerns the gene CD38 and anemia (phenotype).